Orchestra BioMed Surpasses Enrollment Target in AVIM Therapy Trial
Event summary
- Orchestra BioMed completed enrollment in the BACKBEAT Global Pivotal Trial with 330 patients, exceeding the target of 316.
- The trial evaluates AVIM Therapy for uncontrolled hypertension in pacemaker patients, a condition affecting millions globally.
- Primary endpoint data submission is planned for Q2 2027, with potential regulatory filings to follow.
- The trial is a collaboration with Medtronic, which could commercialize AVIM Therapy if approved.
The big picture
Orchestra BioMed's completion of the BACKBEAT Trial marks a critical step in expanding the role of cardiac pacing beyond rhythm management to hypertension treatment. With Medtronic as a strategic partner, the collaboration could reshape the $XX billion global hypertension market if AVIM Therapy gains regulatory approval. The trial's success underscores the growing intersection of bioelectronic therapies and chronic disease management.
What we're watching
- Regulatory Pathway
- Whether the BACKBEAT Trial results will support FDA and global regulatory approvals for AVIM Therapy.
- Commercialization Timing
- The pace at which Medtronic could bring AVIM Therapy to market if approved.
- Clinical Efficacy
- How the primary endpoint data will compare to pilot study results showing significant blood pressure reductions.